New Leaf Venture Partners

Description

New Leaf Venture Partners Invests in $35.4 (GBP 22.4) Million Series A Financing of Convergence Pharmaceuticals October 5, 2010 New Randomized Controlled Trial Supports Efficacy And Safety Of Spiracur SNaP Wound Care System September 27, 2010 First European Filing for Marketing Approval of Osteoporosis Drug September 21, 2010 Daxas ® (roflumilast) data analysis shows reduction in harmful lung attacks September 19, 2010 Relypsa Raises $70 Million in Series B Financing September 13, 2010 Neuronetics selected by World Economic Forum as 2011 Technology Pioneer September 1, 2010 Afferent Pharmaceuticals Announces Data Supporting Potential Utility of Proprietary P2X3 Antagonists in Regulating Bladder Reflexes August 25, 2010 Oxford Immunotec announces US FDA approval of PMA supplement for the use of the T-Cell Xtend ® reagent August 11, 2010 WorldHeart Receives FDA Approval to Add Clinical Sites in Levacor™ VAD Bridge-to-Transplant Study July 27, 2010 Epocrates, Incorporated Files Registration Statement for Proposed Initial Public Offering July 16, 2010 Presidio Pharmaceuticals, Incorporated Successfully Completes Phase 1a Clinical Trial of PPI-461, a Potent, New Hepatitis C Virus (HCV) Inhibitor July 14, 2010 Synageva Biopharma Receives Orphan Drug Designation for SBC-102 for Lysosomal Acid Lipase Deficiency July 7, 2010 ISTA Pharmaceuticals Announces Phase III Results For Once-Daily Topical Xibrom™ 0.09% July 1, 2010 Tolerx Initiates Confirmatory Phase 3 Clinical Trial, DEFEND-2, with Otelixizumab for Type 1 Diabetes June 28, 2010 Tolerx Presents Baseline Data from DEFEND-1 Study Validating C-Peptide as Critical Clinical Measure for New-Onset Type 1 Diabetes June 28, 2010 Olympus to Acquire Spiration, Incorporated, a U.S.

Products & services

Similar companies nearby